EUCTR2008-001175-29-IT进行中（未招募）不适用
Phase II trial evaluating fotemustine (Muphoran) treatment in patients with refractory or relapsing multiple myeloma - ND
OSPEDALE POLICLINICO S. MATTEO0 个研究点开始时间: 2008年3月17日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •patients with refractory or relapsing multiple myeloma treated with at least 3 therapeutic lines (bortezomib, thalidomide and/or lenalidomide) age > 18 years, performance status score > 60%, measurable disease, ...
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •pregnancy, lactation, concomitant immunotherapy, biologic therapy or sperimental drug, ...
研究者
相似试验
进行中（未招募）
不适用
Phase II multicenter study with Fotemustine and Temozolomide modulation in patients with metastatic melanoma (MM) - Phase II multicenter study with Fotemustine and Temozolomide in MMPatients with metastatic melanoma non pre-treated for advanced diseaseMedDRA version: 12.1Level: LLTClassification code 10027481Term: Metastatic melanomaEUCTR2009-016487-36-ITGOIM GRUPPO ONCOLOGICO MERIDIONALE
进行中（未招募）
1 期
A randomized, Phase III study of Fotemustine versus the Combination of Fotemustine and Ipilimumab in Patients with Metastatic Melanoma with brain metastasisEUCTR2012-004301-27-ITFONDAZIONE NIBIT160
进行中（未招募）
不适用
Second line therapy with low dose fotemustine in progressive malignant gliomas - fotgmProgressive malignant gliomas patientsMedDRA version: 9.1Level: LLTClassification code 10006131Term: Brain neoplasm malignantEUCTR2008-003342-29-ITISTITUTI FISIOTERAPICI OSPITALIERI
进行中（未招募）
不适用
Study to learn if 200mg test drug (Fostamatinib) helps people with Large B-Cell Lymphoma, a type of blood cancerDiffuse Large B-cell LymphomaMedDRA version: 16.1Level: LLTClassification code 10012820Term: Diffuse large B-cell lymphoma NOSSystem Organ Class: 100000004864EUCTR2011-005371-16-GBRigel Pharmaceuticals, Inc.60
已完成
2 期
Vemurafenib + Fotemustine to Treat Advanced Melanoma Patients With V600BRAF Mutation Recurred While on VemurafenibMalignant Melanoma Stage IVNCT01983124Paola Queirolo31